As the newly appointed research leader at K2, this is my first editorial in K2-nytt. I am a medical specialist in infectious diseases and completed a PhD in 2012 on clinical and immunological analyses of patients with long-term complaints following the Giardia outbreak in 2004. Since then, I have researched diarrheal diseases and immunology with Giardia, ETEC, and Cryptosporidium as my favorite microbes.
In my new role, there is much I want to familiarize myself with. I have started by getting an overview of the research activities at K2. Measured in publications, K2 is involved in around 480 scientific articles per year. This has been stable over the past four years. 65% of our publications have international co-authorship, and 89% are published with open access. It is gratifying that the proportion of high-quality publications, published in the more selective level-2 journals, has shown positive development from 18% in 2021 to 25% in 2023. Our research publication relative to our number of first positions and full-time equivalents has remained stable in recent years.
The goal must be to maintain or improve the quality and research production at K2 despite tight finances and necessary cost-saving measures that must be implemented this year and next year. We managed to keep going through the pandemic, and I see it as an important task for me in my role as research leader at K2 to help ensure that we achieve this in the future as well.
I have an office on the 5th floor of the Lab building if you want to have a chat with me. For those interested in more publication statistics from UiB, this can be found at https://bibliometri.w.uib.no/
